These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9489847)

  • 1. Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis.
    Roux S; Seelig HP; Meyer O
    J Rheumatol; 1998 Feb; 25(2):395-6. PubMed ID: 9489847
    [No Abstract]   [Full Text] [Related]  

  • 2. [Polymyositis/dermatomyositis and autoantibodies].
    Hirakata M; Mitsumori K; Akizuki M
    Nihon Rinsho Meneki Gakkai Kaishi; 1996 Dec; 19(6):588-93. PubMed ID: 9081723
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical significance of specific autoantibodies in juvenile dermatomyositis.
    Feldman BM; Reichlin M; Laxer RM; Targoff IN; Stein LD; Silverman ED
    J Rheumatol; 1996 Oct; 23(10):1794-7. PubMed ID: 8895161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
    Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
    Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti PM-Scl antibodies. Study of prevalence and of meaning].
    Gaudin C; Fortenfant F; Adoue D; Beyne-Rauzy O
    Rev Med Interne; 2006 Sep; 27(9):665-70. PubMed ID: 16797795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of anti-Ro52α and anti-Ro52β antibodies in dermatomyositis/polymyositis.
    Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Akiyama M
    J Dermatol Sci; 2019 Oct; 96(1):50-52. PubMed ID: 31444014
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunoserological aspects of idiopathic inflammatory muscle disease.
    Rozman B; Bozic B; Kos-Golja M; Plesivcnik-Novljan M; Kveder T
    Wien Klin Wochenschr; 2000 Aug; 112(15-16):722-7. PubMed ID: 11020964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunological aspects of polymyositis].
    Takayanagi T; Honda H
    No To Shinkei; 1983 Jun; 35(6):525-33. PubMed ID: 6354219
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis.
    Komura K; Fujimoto M; Matsushita T; Kaji K; Kondo M; Hirano T; Orito H; Horikawa M; Hamaguchi Y; Hasegawa M; Takehara K; Sato S
    J Dermatol Sci; 2005 Dec; 40(3):215-7. PubMed ID: 16289693
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical and pathological investigation of polymyositis and dermatomyositis: report of 83 cases].
    Li Q; Lu BX; Zhou L; An SL
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Dec; 22(12):1139-40. PubMed ID: 12480599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymyositis and dermatomyositis: pathophysiology.
    Nagaraju K; Lundberg IE
    Rheum Dis Clin North Am; 2011 May; 37(2):159-71, v. PubMed ID: 21444017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of 52-kd and 60-kd Ro/SS-A autoantibodies in Japanese patients with polymyositis/dermatomyositis.
    Kubo M; Ihn H; Asano Y; Yamane K; Yazawa N; Tamaki K
    J Am Acad Dermatol; 2002 Jul; 47(1):148-51. PubMed ID: 12077598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polymyositis and dermatomyositis in adults].
    Matsubara S
    Ryoikibetsu Shokogun Shirizu; 2001; (35):284-90. PubMed ID: 11555932
    [No Abstract]   [Full Text] [Related]  

  • 14. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells.
    Fasth AE; Dastmalchi M; Rahbar A; Salomonsson S; Pandya JM; Lindroos E; Nennesmo I; Malmberg KJ; Söderberg-Nauclér C; Trollmo C; Lundberg IE; Malmström V
    J Immunol; 2009 Oct; 183(7):4792-9. PubMed ID: 19752224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.
    Kao AH; Lacomis D; Lucas M; Fertig N; Oddis CV
    Arthritis Rheum; 2004 Jan; 50(1):209-15. PubMed ID: 14730618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease in polymyositis and dermatomyositis.
    Marie I; Hachulla E; Chérin P; Dominique S; Hatron PY; Hellot MF; Devulder B; Herson S; Levesque H; Courtois H
    Arthritis Rheum; 2002 Dec; 47(6):614-22. PubMed ID: 12522835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis].
    Cherin P
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S48-50. PubMed ID: 10896990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis.
    Aleksza M; Szegedi A; Antal-Szalmás P; Irinyi B; Gergely L; Ponyi A; Hunyadi J; Sipka S; Zeher M; Szegedi G; Dankó K
    Ann Rheum Dis; 2005 Oct; 64(10):1485-9. PubMed ID: 15829578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of autoantibody screening in patients with autoimmune myositis.
    Ghirardello A; Zampieri S; Tarricone E; Iaccarino L; Bendo R; Briani C; Rondinone R; Sarzi-Puttini P; Todesco S; Doria A
    Autoimmunity; 2006 May; 39(3):217-21. PubMed ID: 16769655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Polymyositis/scleroderma autoantibody-positive scleroderma with dermatomyositis (scleromyositis)].
    Török L; Dankó K; Cserni G; Szücs G
    Orv Hetil; 2002 Nov; 143(45):2553-6. PubMed ID: 12501562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.